<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Advantages and disadvantages of different anticoagulants for treatment of venous thromboembolism in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Advantages and disadvantages of different anticoagulants for treatment of venous thromboembolism in children and adolescents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Advantages and disadvantages of different anticoagulants for treatment of venous thromboembolism in children and adolescents</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Â </td> <td class="subtitle1">LMWH</td> <td class="subtitle1">Unfractionated heparin</td> <td class="subtitle1">DOACs</td> <td class="subtitle1">Vitamin K antagonists<br/> (eg, warfarin)</td> </tr> <tr class="divider_bottom divider_top"> <td><strong>Predictability of anticoagulant response</strong></td> <td>Response is highly predictable</td> <td>Response is less predictable (compared with LMWH)</td> <td>Response is predictable</td> <td>Response is unpredictable</td> </tr> <tr class="divider_bottom"> <td><strong>Ease of administration</strong></td> <td>Does not require IV access, but subcutaneous administration may be bothersome to patients</td> <td>Requires IV access</td> <td>Orally administered</td> <td>Orally administered</td> </tr> <tr class="divider_bottom"> <td><strong>Pediatric-specific oral formulation</strong></td> <td>N/A (drug is given parenterally)</td> <td>N/A (drug is given parenterally)</td> <td>Pediatric formulations are available for dabigatran and rivaroxaban</td> <td>Available only in tablet form</td> </tr> <tr class="divider_bottom"> <td><strong>Need for laboratory monitoring and dose adjustment</strong></td> <td>Requires only periodic monitoring</td> <td>Requires frequent monitoring and dose adjustment</td> <td>No required monitoring</td> <td>Requires frequent monitoring and dose adjustment</td> </tr> <tr class="divider_bottom"> <td><strong>Impact of diet on drug's effect</strong></td> <td>Little impact</td> <td>Little impact</td> <td>Little impact</td> <td>Effectiveness is impacted by vitamin K intake, which can have considerable variation in children's diets</td> </tr> <tr class="divider_bottom"> <td><strong>Reversibility</strong></td> <td>IV protamine can be used to reverse anti-Xa activity, but reversal is not complete</td> <td>Can easily be reversed with IV protamine; stopping the infusion is often sufficient to control minor bleeding</td> <td>Reversal agents for DOACs have not been studied in children, and they are not universally readily available</td> <td>Can be reversed with vitamin K administration</td> </tr> <tr class="divider_bottom"> <td><strong>Long-term use</strong></td> <td> <ul> <li>Data on long-term safety in children are limited</li> <li>May reduce bone density, but risk is likely lower than with unfractionated heparin or vitamin K agonist</li> </ul> </td> <td>Generally not used for long-term management</td> <td> <ul> <li>Limited experience</li> <li>Data on long-term safety in children are lacking</li> </ul> </td> <td> <ul> <li>Extensive experience with long-term use </li> <li>May reduce bone density</li> </ul> </td> </tr> <tr> <td colspan="5"><strong>Special considerations:</strong></td> </tr> <tr> <td class="indent1">Kidney failure</td> <td> <ul> <li>For patients with mild renal insufficiency, dose adjustment and close monitoring may be necessary</li> <li>For those with severe renal failure, LMWH should be avoided</li> </ul> </td> <td>Dose adjustment is not necessary</td> <td> <ul> <li>Limited data on use in children with renal impairment</li> <li>For patients with mild renal insufficiency, dose adjustment is not necessary </li> <li>For those with severe kidney failure, DOACs should be avoided</li> </ul> </td> <td>Dose adjustment is not necessary</td> </tr> <tr> <td class="indent1">Liver failure</td> <td>Dose adjustment is not necessary</td> <td>Dose adjustment is not necessary</td> <td> <ul> <li>For dabigatran, dose adjustment is not necessary </li> <li>Rivaroxaban should not be used in patients with severe hepatic failure </li> </ul> </td> <td>For patients with mild liver dysfunction and/or elevated baseline prothrombin time, dose adjustment and close monitoring are necessary; for those with severe liver failure, warfarin should be avoided</td> </tr> <tr> <td class="indent1">Pregnancy</td> <td>Does not cross the placenta, and does not result in fetal anticoagulation</td> <td>Does not cross the placenta, and does not result in fetal anticoagulation</td> <td>Should not be used during pregnancy, due to increased reproductive risks in animal studies</td> <td>Should not be used during pregnancy (particularly 1<sup>st</sup> trimester), because it crosses the placenta, is a teratogen, and causes fetal anticoagulation</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes the advantages and disadvantages of the major classes of anticoagulants used in pediatric patients. Enoxaparin is the most commonly used LMWH agent in children. Warfarin is the most common VKA agent. Dabigatran and rivaroxaban are the only DOACs that are approved for use in pediatric patients. The choice of anticoagulant agent is influenced by patient comorbidities, drug interactions, clinician preference and experience (eg, familiarity with newer DOAC agents), and other considerations specific to each drug (eg, cost, availability, formulation, ease of administration, and need for monitoring). Decisions should be individualized weighing the benefits and risks and considering the values and preferences of the individual patient/family. For additional details, refer to separate UpToDate content on management of venous thromboembolism in children.</div><div class="graphic_footnotes">LMWH: low molecular weight heparin; DOACs: direct oral anticoagulants; IV: intravenous; N/A: not applicable.</div><div id="graphicVersion">Graphic 114581 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
